Our Pipeline

Skyhawk is advancing a diverse pipeline of RNA-targeted small molecule therapies across neurology, oncology, and fibrotic disease.

Clinical & Preclinical Programs

Asset	Target	Indication	Area	Partner	Development Stage
SKY-0515	HTT	Huntington's Disease	Neurology	Skyhawk	Preclinical Phase 1 Phase 2 Phase 3 Phase 2/3
SKY-0925	Undisclosed	Rare Neurological Disease	Neurology	Skyhawk	Preclinical Phase 1 Phase 2 Phase 3 Preclinical
SKY-4100	Undisclosed	Rare Neurological Disease	Neurology	Skyhawk	Preclinical Phase 1 Phase 2 Phase 3 Preclinical
SKY-2100	Undisclosed	Rare Neurological Disease	Neurology	Skyhawk	Preclinical Phase 1 Phase 2 Phase 3 Preclinical
Undisclosed	Undisclosed	Undisclosed	Undisclosed	Genentech	Preclinical Phase 1 Phase 2 Phase 3 Preclinical
Undisclosed	Undisclosed	Undisclosed	Undisclosed	Sanofi	Preclinical Phase 1 Phase 2 Phase 3 Preclinical
Undisclosed	Undisclosed	Undisclosed	Undisclosed	Merck KGaA	Preclinical Phase 1 Phase 2 Phase 3 Preclinical
Undisclosed	Undisclosed	Undisclosed	Undisclosed	Takeda	Preclinical Phase 1 Phase 2 Phase 3 Preclinical
Undisclosed	Undisclosed	Undisclosed	Undisclosed	Bristol Myers Squibb	Preclinical Phase 1 Phase 2 Phase 3 Preclinical
Undisclosed	Undisclosed	Undisclosed	Undisclosed	Merck	Preclinical Phase 1 Phase 2 Phase 3 Preclinical
Undisclosed	Undisclosed	Undisclosed	Undisclosed	Ipsen	Preclinical Phase 1 Phase 2 Phase 3 Preclinical